

## Record quarterly revenue: €10.1 million in the 1<sup>st</sup> quarter of 2023, organic growth +16%

- **Radiology:** 6% growth in 1<sup>st</sup> quarter /+22% in the United States  
First deliveries of record order from Fujifilm Healthcare Italy will begin 2<sup>nd</sup> quarter
- **Bone densitometry:** strong quarterly growth: +69%

### Confirmation of 2023 targets and perspectives

- **€40 million in revenue**, i.e., double-digit organic growth
- **Expected increase in EBITDA margin**

Liège (Belgique) - **DMS Imaging (Euronext Brussels and Paris - BE0974289218 - DMSIM)**, imaging division of DMS Group and French specialist in the development, design and manufacture of imaging systems, announces its consolidated revenue for the 1<sup>st</sup> quarter of 2023 (period from January 1 to March 31, 2023).

Unaudited consolidated data in M€ IFRS standards	1 <sup>st</sup> quarter 2023	1 <sup>st</sup> quarter 2022	Change
<b>Revenue</b>	<b>10.1</b>	<b>8.7</b>	<b>+16%</b>
Radiology activity	7.7	7.3	+6%
Bone densitometry activity	2.4	1.4	+69%

DMS Imaging generated consolidated revenue of €10.1 million in the 1<sup>st</sup> quarter 2023 representing +16% of organic growth and marking the largest quarterly revenue ever earned in a 1<sup>st</sup> quarter.

#### Review by activity

In **Radiology**, revenue amounted to €7.7 million, a quarterly growth of +6%. 1<sup>st</sup> quarter activity did not include any deliveries of the 96 FDX Visionary-RF Premium remote-controlled radiology tables won in a tender by Fujifilm Healthcare Italy<sup>1</sup>. The first deliveries for this order will begin in the 2<sup>nd</sup> quarter of 2023 and will ramp up throughout the year.

The Radiology business continued its strong development in the United States at the start of the exercise, with +22% growth in the region, driven by distribution agreements with Fujifilm Healthcare and Carestream Health. DMS Imaging manufactures white-label remote-controlled radiology tables offered by:

- Fujifilm Healthcare in Europe, Africa, Middle East, and North America.
- Canon Medical Systems Europe in the Europe area.
- Carestream Health in North and South America.

<sup>1</sup> Read press release of January 12, 2023

DMS Imaging also markets its solutions under its own brand, Apelem, to a network of 140 distributors around the world.

In **Bone densitometry**, the Group registered a strong 1<sup>st</sup> quarter 2023, recording +69% growth. This performance reflects the success of our distribution agreement with Fujifilm Healthcare as well as an acceleration in sales in Europe and Asia, where sales activities had begun to resume at the end of 2022.

### Confirmation of 2023 revenue target: €40 million

At the end of an historic 1<sup>st</sup> quarter, DMS Imaging remains confident in its objective of **€40 million consolidated annual revenue**. The Radiology activity will begin deliveries of the 96 tables to Fujifilm Healthcare Italy over the next few quarters, and sustained activity in both radiology and bone densitometry will allow the Group to reach **double-digit organic growth** compared to 2022.

The Group also confirms **the improvement in its profitability in 2023**, with an expected improvement in its EBITDA margin<sup>2</sup>.

As set forth in the **Imaging 2027** plan of DMS Group, DMS Imaging has fixed the objectives of registering €60 million revenue and an EBITDA margin of 14% in 2027.

### Financial calendar 2023

Date	Event
April 28 <sup>th</sup> 2023	Publication of 2022 annual results
July 20 <sup>th</sup> 2023	Publication of 2023 1 <sup>st</sup> semester revenue
September 29 <sup>th</sup> 2023	Publication of 2023 half-year results
October 19 <sup>th</sup> 2023	Publication of 2023 3 <sup>rd</sup> quarter revenue
January 18 <sup>th</sup> 2024	Publication of 2023 annual revenue
April 30 <sup>th</sup> 2024	Publication of 2023 annual results

The publications will be made when the Euronext Paris market is closed. These dates are given as an indication, they can be changed if necessary.

### About DMS Imaging

Specialized in high technology for medical diagnosis, DMS Imaging is now the French leader in development, design, and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

DMS Imaging is quoted on the Euronext market in Brussels and Paris (ISIN : BE0974289218 - mnémo : DMSIM).

More information on [www.dms-imaging.com](http://www.dms-imaging.com).

#### Contacts

##### DMS Imaging

Samuel SANCERNI                      CEO    +33 (0)4 67 50 49 00

##### ACTUS FINANCE

Mathieu OMNES                      Investors relations                      +33 (0)1 53 67 36 92

Fatou-Kiné N'DIAYE                      Press relations                      +33 (0)1 53 67 36 34

<sup>2</sup> EBITDA corresponds to the recurring operating income before interest, taxes, depreciations, and amortization.